Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Holdings Raised by Fisher Asset Management LLC

Fisher Asset Management LLC raised its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 50.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 905,209 shares of the company’s stock after acquiring an additional 302,367 shares during the period. Fisher Asset Management LLC’s holdings in Myriad Genetics were worth $12,410,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd acquired a new position in shares of Myriad Genetics in the 3rd quarter valued at about $32,000. KBC Group NV boosted its holdings in shares of Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock valued at $80,000 after buying an additional 3,334 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after buying an additional 583 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after buying an additional 1,471 shares during the period. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Myriad Genetics by 588.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company’s stock valued at $135,000 after buying an additional 4,207 shares during the period. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Stock Down 3.2 %

MYGN stock opened at $10.39 on Tuesday. Myriad Genetics, Inc. has a 52 week low of $9.76 and a 52 week high of $29.30. The company has a market capitalization of $945.85 million, a price-to-earnings ratio of -7.99 and a beta of 1.88. The firm’s 50-day moving average is $13.21 and its two-hundred day moving average is $18.79. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. During the same quarter last year, the firm posted ($0.12) earnings per share. On average, analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MYGN has been the subject of several research reports. Leerink Partners lowered shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $30.00 to $21.00 in a report on Monday, December 9th. Morgan Stanley decreased their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Bank of America decreased their price target on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a report on Monday. Leerink Partnrs lowered shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Saturday. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $22.00.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.